NO873679L - Fremgangsmaate for fremstilling av faktor viii:c-type proteiner. - Google Patents

Fremgangsmaate for fremstilling av faktor viii:c-type proteiner.

Info

Publication number
NO873679L
NO873679L NO873679A NO873679A NO873679L NO 873679 L NO873679 L NO 873679L NO 873679 A NO873679 A NO 873679A NO 873679 A NO873679 A NO 873679A NO 873679 L NO873679 L NO 873679L
Authority
NO
Norway
Prior art keywords
vwf
factor viii
cells
medium
serum
Prior art date
Application number
NO873679A
Other languages
English (en)
Norwegian (no)
Other versions
NO873679D0 (no
Inventor
Randal J Kaufman
Robert S Adamson
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27124021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO873679(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of NO873679D0 publication Critical patent/NO873679D0/no
Publication of NO873679L publication Critical patent/NO873679L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO873679A 1986-01-03 1987-09-02 Fremgangsmaate for fremstilling av faktor viii:c-type proteiner. NO873679L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81603186A 1986-01-03 1986-01-03
US94233886A 1986-12-16 1986-12-16
PCT/US1987/000033 WO1987004187A1 (en) 1986-01-03 1987-01-02 METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS

Publications (2)

Publication Number Publication Date
NO873679D0 NO873679D0 (no) 1987-09-02
NO873679L true NO873679L (no) 1987-11-02

Family

ID=27124021

Family Applications (1)

Application Number Title Priority Date Filing Date
NO873679A NO873679L (no) 1986-01-03 1987-09-02 Fremgangsmaate for fremstilling av faktor viii:c-type proteiner.

Country Status (8)

Country Link
EP (1) EP0253870B1 (de)
JP (1) JP2525022B2 (de)
AT (1) ATE87663T1 (de)
DE (1) DE3785102T2 (de)
DK (1) DK457587A (de)
FI (1) FI873796L (de)
NO (1) NO873679L (de)
WO (1) WO1987004187A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
WO1988005825A1 (en) * 1987-01-30 1988-08-11 Biogen N.V. A method for producing factor viii in high yield
CA1331157C (en) * 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
ES2060942T3 (es) * 1989-02-02 1994-12-01 Joel S Greenberger Terapia genetica utilizando celulas estromicas.
US7247475B2 (en) 1989-07-28 2007-07-24 Wyeth Method for producing monoclonal antibodies
US6475787B1 (en) 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5371198A (en) * 1991-12-16 1994-12-06 Novo Nordisk A/S Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
EP0910628B1 (de) 1996-04-24 2006-03-08 The Regents of The University of Michigan Gegen inaktivierung resistenter faktor viii
BR9711540A (pt) 1996-09-24 2001-06-19 Protector & Gamble Company Inibidores de protease proteìnico estabilizados e variantes dos mesmos
JP4405668B2 (ja) 1998-03-12 2010-01-27 ジェネティクス インスティテュート，エルエルシー 因子ｖｉｉｉ蛋白を製造するための改良された方法
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
DK1266006T3 (da) * 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
EP1351986A2 (de) 2001-01-12 2003-10-15 The American National Red Cross Verfahren und zusammensetzungen zur verminderung von heparansulfatproteoglykan-vermittelter entfernung von faktor viii
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
EP1988101A1 (de) 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
EP2957628A1 (de) 2010-10-05 2015-12-23 Novo Nordisk Health Care AG Verfahren zur proteinherstellung
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
DK2729161T3 (en) 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN111499761A (zh) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
BR112014017111A8 (pt) 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
EP2858659B1 (de) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Prokoagulationsverbindungen
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
AU2013290173B2 (en) 2012-07-11 2018-02-15 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3970738A1 (de) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blutfaktorüberwachungstest und verwendungen davon
EP2908847B1 (de) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors
EP2914293A4 (de) 2012-10-30 2016-04-20 Biogen Ma Inc Verfahren zur verwendung von fviii-polypeptid
DK2956477T4 (da) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP3666283B1 (de) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Faktor-viii-polypeptidformulierungen
HK1223302A1 (zh) 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
EP3043813B1 (de) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
PH12016501323B1 (en) 2014-01-10 2022-04-29 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN104630131B (zh) * 2015-01-15 2017-08-15 上海交通大学 一种稳定表达人凝血八因子的cho细胞株及其应用
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
TWI904068B (zh) 2017-08-09 2025-11-11 美商生物化學醫療公司 核酸分子及其用途
AU2018338608B2 (en) 2017-09-27 2025-09-11 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
SG11202007114VA (en) 2018-02-01 2020-08-28 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor viii
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
MX2020010369A (es) 2018-04-04 2020-10-22 Sigilon Therapeutics Inc Particulas implantables y metodos relacionados.
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US10654911B1 (en) * 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
JP2022537200A (ja) 2019-06-19 2022-08-24 バイオベラティブ セラピューティクス インコーポレイテッド 血友病および低骨ミネラル密度を処置するための方法および組成物
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
EP4408874A1 (de) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Faktor viii polypeptid kodierende nukleinsäuren mit verminderter immunogenität
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
CN120659872A (zh) 2022-10-11 2025-09-16 西吉隆医疗股份有限公司 用于治疗疾病的经工程化的细胞和可植入元件

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813389A (ja) * 1981-07-16 1983-01-25 Kyowa Hakko Kogyo Co Ltd 細胞培養用培地
JPS5823784A (ja) * 1981-08-04 1983-02-12 Ajinomoto Co Inc 哺乳動物細胞用培地
JPS5913389A (ja) * 1982-07-14 1984-01-24 Matsushita Electric Ind Co Ltd 炭酸ガスレ−ザ発振器
GB2129685B (en) * 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
JPS59166079A (ja) * 1983-03-14 1984-09-19 Morinaga & Co Ltd 細胞培養用培地
JPS59173078A (ja) * 1983-03-22 1984-09-29 Morinaga & Co Ltd 細胞培養用培地
WO1985001961A1 (en) * 1983-10-28 1985-05-09 Genetics Institute Production of factor viii and related products
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
DE3769872D1 (de) * 1986-07-11 1991-06-13 Miles Inc Herstellung von rekombinantem protein.

Also Published As

Publication number Publication date
EP0253870B1 (de) 1993-03-31
NO873679D0 (no) 1987-09-02
FI873796A0 (fi) 1987-09-01
JPS63502318A (ja) 1988-09-08
EP0253870A4 (de) 1988-10-20
DK457587D0 (da) 1987-09-02
EP0253870A1 (de) 1988-01-27
DE3785102D1 (de) 1993-05-06
ATE87663T1 (de) 1993-04-15
FI873796A7 (fi) 1987-09-01
WO1987004187A1 (en) 1987-07-16
DK457587A (da) 1987-11-02
DE3785102T2 (de) 1993-07-22
JP2525022B2 (ja) 1996-08-14
FI873796L (fi) 1987-09-01

Similar Documents

Publication Publication Date Title
NO873679L (no) Fremgangsmaate for fremstilling av faktor viii:c-type proteiner.
EP0362218B1 (de) VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN
US5250421A (en) Method for producing factor VIII:C-type proteins
US5198349A (en) Method for producing factor VIII:C and analogs
EP1266006B1 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
CA1341236C (en) Process for producing recombinant human factor viii: c and transformant to be used therefor
EP0786474B1 (de) Rekombinanter Abkömmling des menschlichen Faktors VIII
JP2022000053A (ja) Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
AU2001254715A1 (en) Production of recombinant blood clotting factors in human cell lines
HU227804B1 (en) Modified factor viii
CA2068728A1 (en) Protein complexes having factor viii:c activity and production thereof
JP3996655B2 (ja) 混合組成物からなるリポソーム様物質の存在中での組換え因子ｖｉｉｉの産生
Kaufman Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology
US5356798A (en) Recombinant protein production in serum-free medium
CA2149212A1 (en) Improved recombinant production of proteins having factor viii:c activity
NO300428B1 (no) Fremgangsmåte ved fremstilling av proteiner med FVIII aktivitet eller FVIII derivater